<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129764</url>
  </required_header>
  <id_info>
    <org_study_id>PUSH-PATH 2</org_study_id>
    <nct_id>NCT02129764</nct_id>
  </id_info>
  <brief_title>Prednisone for Heart Failure Patients With Hyperuricemia</brief_title>
  <acronym>PUSH-PATH-2</acronym>
  <official_title>Prednisone in Uric Acid Lowering in Symptomatic Heart Failure PATients With Hyperuricemia (PUSH-PATH Study 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperuricemia is a very common finding in patients with heart failure. It is usually related
      to diuretic use and deteriorated renal function. The recently evidence showed that prednisone
      and allopurinol may have similar effect on uric acid (UA) lowering in symptomatic heart
      failure patients with hyperuricemia, but prednisone may be superior over allopurinol in renal
      function improvement. Thus the investigators design this randomized head to head study to
      test their hypothesis that prednisone is superior over allopurinol in renal function
      improvement despite their similar effect on UA lowering in heart failure patients with
      hyperuricemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">October 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change form baseline in serum creatinine levels</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in uric acid levels</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Cystatin C</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the levels of tumor necrosis factor (TNF) alfa, interleukin (IL)-1 beta and IL-6 in the circulation</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The levels of angiotensin II and aldosterone in the circulation.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily urine output</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional class</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Heart Failure, Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone will be given 30mg/day for 2 weeks and then tapered off.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol will be given 100 mg/day initially, and then titrated to 200 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic congestive heart failure

          -  18-80 years old

          -  NYHA Class II-IV

          -  Serum uric acid &gt; 7mg/dl

          -  left ventricular ejection fraction â‰¤ 45%

        Exclusion Criteria:

          -  Acute gouty arthritis;

          -  Any condition (other than heart failure) that could limit the use of prednisone or
             xanthine oxidase inhibitors;

          -  Acute decompensated heart failure;

          -  Any concurrent disease that likely limits life expectancy;

          -  Active myocarditis, or an hypertrophic obstructive or restrictive cardiomyopathy;

          -  Myocardial infarction, stroke, unstable angina, or cardiac surgery within the previous
             3 months;

          -  Indication for hemodialysis

          -  Creatinine&gt; 3.0 mg per deciliter at admission to the hospital

          -  Uncontrolled systolic blood pressure &gt; 160 mmHg

          -  Known bilateral renal artery stenosis

          -  Complex congenital heart disease

          -  Any signs of infections

          -  Enrollment in another clinical trial involving medical or device-based interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kunshen Liu</last_name>
    <phone>8631185917033</phone>
    <email>ksliud@sohu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chao Liu</last_name>
    <phone>8631185917032</phone>
    <email>dr.liuchao@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunshen Liu</last_name>
      <phone>8631185917033</phone>
      <email>ksliud@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Kuns Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2014</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Kun-shen Liu M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

